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Abstract
Sporadic Creutzfeldt-Jakob disease (sCJD) cases are currently subclassified according to the methionine/valine
polymorphism at codon 129 of the PRNP gene and the proteinase K (PK) digested abnormal prion protein (PrP
res)
identified on Western blotting (type 1 or type 2). These biochemically distinct PrP
res types have been considered to
represent potential distinct prion strains. However, since cases of CJD show co-occurrence of type 1 and type 2 PrP
res in the
brain, the basis of this classification system and its relationship to agent strain are under discussion. Different brain areas
from 41 sCJD and 12 iatrogenic CJD (iCJD) cases were investigated, using Western blotting for PrP
res and two other
biochemical assays reflecting the behaviour of the disease-associated form of the prion protein (PrP
Sc) under variable PK
digestion conditions. In 30% of cases, both type 1 and type 2 PrP
res were identified. Despite this, the other two biochemical
assays found that PrP
Sc from an individual patient demonstrated uniform biochemical properties. Moreover, in sCJD, four
distinct biochemical PrP
Sc subgroups were identified that correlated with the current sCJD clinico-pathological classification.
In iCJD, four similar biochemical clusters were observed, but these did not correlate to any particular PRNP 129
polymorphism or western blot PrP
res pattern. The identification of four different PrP
Sc biochemical subgroups in sCJD and
iCJD, irrespective of the PRNP polymorphism at codon 129 and the PrP
res isoform provides an alternative biochemical
definition of PrP
Sc diversity and new insight in the perception of Human TSE agents variability.
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Introduction
Transmissible spongiform encephalopathies (TSE) are neuro-
degenerative disorders affecting a large spectrum of mammalian
species that share similar characteristics, including a long
incubation period (which in man may be measured in decades)
and a progressive clinical course resulting in death [1].
The most common form of human TSE is an idiopathic
disorder named sporadic Creutzfeldt-Jakob disease (sCJD). sCJD is
not a uniform disorder in terms of its clinical and neuropatholog-
ical phenotype. It remains unclear whether this variability is
related to variations in the causative TSE agent strains, or to the
influence of the methionine/valine polymorphism at codon 129 of
the PRNP [2,3].
A key event in the pathogenesis of TSE is the conversion of
the normal cellular prion protein (PrP
C, which is encoded by the
PRNP gene) into an abnormal disease-associated isoform (PrP
Sc)
in tissues of infected individuals. Conversion of PrP
C into PrP
Sc
is a post-translational process involving structural modifications
of the protein and resulting in a higher b-sheet content [4]. PrP
C
is completely degraded after controlled digestion with proteinase
K (PK) in the presence of detergents. PrP
Sc is N-terminally
truncated under such conditions, resulting in a PK resistant
core, termed PrP
res [5]. PrP
res, also named PrP 27–30, is a
disease marker for TSE and the presence of PrP
Sc seems to
correlate with infectivity [5,6]. According to the prion
hypothesis, PrP
Sc is the infectious agent in TSE [7] and, in
the last decades, several lines of evidence have indicated that
particular biochemical properties of PrP
Sc, such as solubility in
N-lauroylsarcosine, PK resistance and electromobility in western
blotting (WB) can be used to distinguish between different prion
agents or strains [8,9].
PLoS Pathogens | www.plospathogens.org 1 2008 | Volume 4 | Issue 3 | e1000029In sCJD, two major PrP
res types have been described by WB: in
type 1 PrP
res, the unglycosylated fragment is 21 kDa, while in type
2, the apparent molecular weight of this unglycosylated fragment is
19 kDa [3]. Protein N-terminal sequencing revealed that type 2
isoform derives from preferential cleavage of the protein during
PK digestion at amino acid 97, while in type 1 preferential
cleavage occurs at amino acid 82 [10]. sCJD cases can be
subclassified according the PrP
res isoform and the PRNP codon
129 methionine (M)/valine (V) polymorphism, resulting in 6 major
subypes: MM1, MM2, MV1, MV2, VV1 and VV2. Interestingly,
these subtypes appear to carry distinct pathological and clinical
features, [2,3], and it has been proposed that type 1 and type 2
isoforms in sCJD might correspond to different TSE agent strains.
However, the description of PrP
res isoforms which appear to be
distinct from type 1 and type 2, and the increasing number of
reports describing the coexistence of type 1 and type 2 PrP
res in
different areas or the same area in the brain from a single sCJD
patient, calls into questions the subclassification system described
above in sCJD [11–14]. Here, in a large group of cases including
41 sCJD and 12 iCJD patients, we confirmed that type 1 and type
2 PrP
res can be observed as a mixture in a substantial number of
patients. However, using two novel assays described here, PrP
Sc
from these patients with mixed PrP
res types are homogeneous
irrespective of the brain area considered. Moreover, based on
these novel PrP
Sc biochemical properties, four distinct subgroups
were observed in our cohort of sCJD patients. Similar findings
were observed in iCJD cases from two countries and differing
sources of infection.
Materials and Methods
Cases Studied
A total of 41 French cases of sCJD, each of which had frozen
tissue (2–4 g) available from preferentially 5 brain regions:
(occipital, temporal and frontal cortex, cerebellum and the caudate
nucleus), were included in this study. All six currently defined
classes of s-CJD patients (MM1-MM2-MV1-MV2-VV1-VV2)
were represented in our panel (Table 1). Moreover, 12 cases of
iatrogenic CJD (iCJD), linked to contamination by growth
hormone (GH) or dura mater grafts, from patients originating
either from United Kingdom (UK) or France, were also
investigated (Table 1). None of the patients had a familial history
of prion disease and, in each case, the entire PRNP coding
sequence was analyzed, either by denaturating gradient gel
electrophoresis and/or direct sequencing. All patients died from
CJD during the period 1997–2004. Additionally, five cases of
Alzheimer’s disease were included as non-CJD controls.
In all cases, informed consent for research was obtained and the
material used had appropriate ethical approval for use in this
project.
Tissue Homogenate Preparation
For each sample, a 20% brain homogenate (weight/volume) in
5% glucose was prepared using a high-speed homogenizer (TeSeE
Precess 48 system). The homogenates were then filtered through a
20 Gauge needle before storage at 280uC.
Western Blot PrP
sc Banding Pattern
Various factors have been reported to influence the results of
PrP
res analysis by WB, including tissue pH and the effect of Cu
2+
ions [15–17]. In order to limit these factors, each homogenate was
diluted a 100-fold in a single non-CJD control brain homogenate
prior to further investigation.
A WB kit (TeSeE WB kit Bio-Rad) was used following the
manufacturer’s recommendations.
Three different monoclonal PrP-specific antibodies were used
for PrP detection: Sha31 (1 mg/ml) [18], 8G8 (4 mg/ml) [19] and
12B2 (4 mg/ml) [20], which recognized the amino acid sequences
YEDRYYRE (145–152), SQWNKPSK (97–104) and WGQGG
(89–93) respectively. After incubation with goat anti-mouse IgG
antibody conjugated to horseradish peroxidase, signal was
visualized using the ECL western blotting detection system by
enhanced chemiluminescent reaction (ECL, Amersham). Molec-
ular weights were determined with a standard protein preparation
(MagicMark, Invitrogen).
PrP
Sc Resistance ELISA
PrP
Sc detection was carried out using sandwich ELISA test
(TeSeE CJD, Bio-Rad) used following the manufacturer’s recom-
mendations. The assay protocol includes a preliminary purification
of the PrP
Sc (TeSeE purification kit) consisting in (i) digestion of
PrP
C with PK, (ii) precipitation of PrP
Sc by buffer B and
centrifugation, (iii) denaturation of PrP
Sc in buffer C at 100uC,
before immuno-enzymatic detection. In this ELISA, the capture
antibody3B5recognizestheoctarepeatregionofPrP[19],whilethe
detection antibody 12F10 binds to the core part of the protein [18].
PK resistance of the PrP
Sc portion recognized in the ELISA test
was determined by measurement of the ELISA specific signal
recovered from a series of homogenate aliquots digested with
different concentrations of PK in buffer A9 reagent (TeSeE Sheep/
Goat purification kit). Each sample was first diluted in normal
brain homogenate (between 100- and 10,000-fold) until obtaining
a signal between 1.5 and 2 absorbance units after digestion with
50 mg/ml of PK. Triplicate of equilibrated samples were then
submitted to a PK digestion with concentrations ranging from 50
to 500 mg/ml, before PrP
Sc precipitation and ELISA detection.
Results were expressed as the percentage of residual signal when
compared to the 50 mg/ml PK digestion (lowest PK concentra-
tion). In each assay, two standardized controls (scrapie and BSE
Author Summary
Prion diseases are transmissible neurodegenerative disor-
ders characterized by accumulation of an abnormal
isoform (PrP
Sc) of a host-encoded protein (PrP
C) in affected
tissues. According to the prion hypothesis, PrP
Sc alone
constitutes the infectious agent. Sporadic Creutzfeldt-
Jakob disease (sCJD) is the commonest human prion
disease. Although considered as a spontaneous disorder,
the clinicopathological phenotype of sCJD is variable and
substantially influenced by the methionine/valine poly-
morphism at codon 129 of the prion protein gene (PRNP).
Based on these clinicopathological and genetic criteria, a
subclassification of sCJD has been proposed. Here, we
used two new biochemical assays that identified four
distinct biochemical PrP
Sc subgroups in a cohort of 41
sCJD cases. These subgroups correlate with the current
sCJD subclassification and could therefore represent
distinct prion strains. Iatrogenic CJD (iCJD) occurs follow-
ing presumed accidental human-to-human sCJD transmis-
sion. Our biochemical investigations on 12 iCJD cases from
different countries found the same four subgroups as in
sCJD. However, in contrast to the sCJD cases, no particular
correlation between the PRNP codon 129 polymorphism
and biochemical PrP
Sc phenotype could be established in
iCJD cases. This study provides an alternative biochemical
definition of PrP
Sc diversity in human prion diseases and
new insights into the perception of agent variability.
PrPres Diversity and s and i CJD
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samples were randomly selected and submitted to two indepen-
dent tests separated in time as to assess inter-assay variation.
‘‘Strain Typing’’ ELISA
The ELISA test used in this study was adapted from the Bio-
Rad TeSeE test, validated at CEA for EU strain typing studies in
ruminants and designed to distinguish BSE in sheep from scrapie.
The principle was to measure conformational variations in PrP
Sc
by applying two differential PK digestions under the modification
of detergent conditions (SDS sensitivity). For each sample, PK
digestion was performed under two conditions: (i) two aliquots of
250 ml of 20% homogenate were mixed either with 250 mlo fA
reagent (TeSeE purification kit) containing 20 mg of PK, (ii) with
250 mlo fA 9 reagent (N-lauroylsarcosine sodium salt 5% (W/V),
Figure 1. PrP
res Profiles in sCJD Patients. (A) PrP
res from cerebellum (lane 1), caudate nucleus (lane 2), frontal cortex (lane 3) and occipital cortex
(lane 4) of a single MV patient was extracted and submitted to WB. Detection with antibody Sha31 reveals different PrP
res profiles. (B–D) PrP
res in
cerebellum from seven different patients using Sha31 mAb (B), 8G8 mAb (C), and 12B2 mAb (D). Because of their epitope, Sha31 and 8G8 can detect
both type 1 and type 2 PrP
res while 12B2 detects type 1 only. Lane 1, MM patient; lane 2, MV patient; lane 3, VV patient; lane 4, MV patient; lane 5, MV
patient; lane 6, VV patient; lane 7, MM patient; line 8, sheep BSE control. (E, F) PrP
res profile in temporal cortex from three MV patients revealed by
Sha31 mAb (E) or 12B2 mAb (F).
doi:10.1371/journal.ppat.1000029.g001
PrPres Diversity and s and i CJD
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tubes were then mixed by inversion 10 times and incubated at
37uC (in a water bath) for exactly 15 min. Subsequently, 250 mlo f
reagent B (Bio-Rad purification kit)/PMSF (final concentration
4 mM) were added, mixed and the tubes were centrifuged for
5 minutes at 20,000 g at 20uC. Supernatants were discarded and
tubes dried by inversion onto an absorbent paper for 5 min. Each
pellet was denatured for 5 min at 100uC with 25 ml of C reagent
(Bio-Rad purification kit). The samples were diluted in 250 mLo f
R6 buffer containing 4 mM of serine protease inhibitor AEBSF (4-
2-aminoethyl benzenesulfonyl fluoride hydrochloride), and, if
desired, further serially diluted in R6 buffer. ELISA plates were
then incubated for two hours at room temperature and, after three
washes, antibody detection (TeSeE CJD, Bio-Rad) was added for
two hours at 4uC. The ratio of the absorbance obtained in the two
conditions (A/A9) was calculated using appropriate dilutions
providing absorbance measurements ranging from 0.5 to 2.5
absorbance units in A conditions. For each plate, the same three
control samples (one MM1, one VV2 and one MM GH) were
included. To avoid inter-assay variations, final results were
expressed as a normalized ratio established by dividing the ratio
obtained for the analyzed sample by the one obtained for a VV2
sample selected as standard.
Results
Intra-Individual Variability of WB Banding Pattern
For each sCJD case, PrP
res profile was determined from five
brain areas using both Sha31 and 8G8 antibodies. A single PrP
res
type (type 1 or type 2) was observed in investigated brain areas of
most of the MM1 (n=11), and all the areas from MV1 (n=8),
VV1 (n=1) and MM2 (n=3) sCJD cases of our panel. However,
in several cases initially classified as MM1 (n=2), and in a majority
of VV2 (n=5) or MV2 (n=6) cases, some brain areas harboured
mixed electrophoretic pattern characterized by two distinct bands
at 19 and 21 kDa, indicating the coexistence of PrP
res type 1 and
type 2 (Table 1 and Figure 1A). Moreover, in individual patients
some brain areas were found to be type 1, while another area
could be found to be type 2 (Table 1 and Figure 1A). Since both
Sha31 and 8G8 gave similar results this phenomenon cannot be
attributed to some antibody peculiarity in PrP recognition
(Figure 1B and 1C).
Antibody 12B2 is specific for the amino acid sequence 89–93 that
is located N-terminally of the type 2 cleavage site (amino acid 97). In
principle, this antibody is unable to recognize type 2 PrP
res.
Systematic western blotting with 12B2 consistently demonstrated
the presence of the 21 kDa band, characteristic for type 1 PrP
res,i n
nearlyalltype 2 classified samples,regardlessofthePRNP codon 129
polymorphism (Figure 1D). In a limited number of type 2 samples,
12B2 failed to detect a type 1 band (Figure 1E and 1F, lane 2,3).
Using Sha31 or 8G8, mixed type 1/type 2 PrP
res profiles were
observed in several iCJD cases (Figure 2A), regardless of their
national origin or mode of infection. In most (but not all) samples
initially classified as type 2, the 12B2 antibody revealed the
presence of a 21 kDa band, characteristic of type 1 PrP
res
(Figure 2B).
Together these findings point to the existence of variable
amounts of type 1 PrP
res molecules in all or nearly all type 2
classified patients (Table 1).
All Brain Areas from a Single Patient Have Similar PrP
Sc
Features
In sCJD and iCJD patients who harboured a single WB PrP
Sc
type in the different brain areas, as assessed by Sha31, a single
ELISA PK resistance profile (Table 1 and Figure 3A) and a
comparable ratio in strain typing assay (Table 1 and Figure 3B)
were observed in all brain areas. Surprisingly, in each patient
harbouring both type 1 and 2 PrP
res, either in the same or in
different brain areas, a single ELISA PK digestion profile (Table 1
and Figure 3C and 3D) and a comparable signal ratio in strain
typing assay (Table 1 and Figure 3B) was also observed,
irrespective of region assayed.
MM1 and VV2 samples but also MM2 and VV1 samples,
which harboured similar apparent PrP
Sc content (as assessed by
ELISA) were artificially mixed in different proportions. Using WB,
a mixed type 1+2 profile could, or could not, be observed
depending on the mixture proportions (Figure 3E and 3F). Both
PrP
Sc resistance ELISA assay (Figure 3G and 3H) and strain
typing ELISA (not shown) were able to discriminate the different
mixtures from the original isolates and from each other. These
results clearly demonstrate that the uniformity of PrP
Sc biochem-
ical properties, as demonstrated by both PrP
Sc resistance ELISA
and strain typing ELISA, in patients harbouring different PrP
res
isoforms cannot be attributed to a lack of discriminative power of
these techniques.
Together, these data strongly indicate that, despite possible
variations in PrP
res type on WB analysis, patients with either sCJD
or iCJD appear to harbour a single PrP
Sc isoform in their brain.
Four Distinct PrP
Sc Biochemical Signatures Are Observed
in iCJD and sCJD Patients
According to the results from PrP
Sc PK resistance assay and
strain typing ELISAs, sCJD patients could be split into four groups
(Table 1, and Figure 3A and 3B). The first group was
characterized by a strong PK resistance (Figure 3A) and a low
ratio in strain typing assay (Figure 3B). Group 1 could be readily
differentiated from Group 2 which showed a higher sensitivity
regarding PK digestion, as well as an increased signal ratio in
strain typing assay, when compared to Group 1. Two other PrP
Sc
groups were also observed. Group 3 harboured an intermediate
PK lability in the PrP
Sc resistance ELISA and ratio in the strain
typing ELISA, when compared to Group 1 and 2. Group 4 had a
very high PK-sensitivity and ratio in the strain typing ELISA. No
overlapping in PK resistance profile or ratio value in strain typing
assay were observed between the four determined groups (Table 1).
Figure 2. PrP
res Profiles in iCJD Patients. PrP
res (frontal cortex) was
revealed in WB by antibodies Sha31 (A) and 12B2 (B). Lane 1, MM UK
dura mater patient; lane 2, VV French dura mater patient; lane 3, MM GH
French patient; lane 4, French MV GH patient; lane 5, MV UK GH patient;
lane 6, VV UK GH patient.
doi:10.1371/journal.ppat.1000029.g002
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PLoS Pathogens | www.plospathogens.org 5 2008 | Volume 4 | Issue 3 | e1000029Figure 3. PrPsc PK Resistance and Molecular Strain Variations in sCJD and iCJD Brain Samples. Each investigated brain sample was
initially characterized by WB using antibody Sha31. Symbol patterns represent type 1 in white, type 1+2 in grey and type 2 in black. (A) Results from
PK resistance ELISA carried out on three different brain areas (cerebellum, caudate nucleus and temporal cortex) from a MM1 (open circles), a VV1
(open triangles), a VV2 (inverted filled triangle) and a MM2 (filled squares) sCJD patient. Values obtained are expressed as percentage of signal
obtained with the lowest PK concentration (50 mg/mL). (B) Results from CEA strain typing ELISA (one symbol per patient—3 to 5 different areas by
patients). PrP
Sc signal intensity was measured after PK digestion into two different detergent solutions. Normalized A/A9 ratio was calculated for each
sample (see Methods section). MM1 and MV1 had a low ratio indicating an absence of alteration of PrP
sc PK sensitivity linked to the modification
detergent digestion conditions. This ratio was higher in MV2, VV2, MV1+2, and VV1+2, while, in the unique VV1 case, an intermediate ratio was
observed. In MM2 patients, the huge ratio indicated a strong increase in PK sensitivity by modification of detergent conditions. (C, D) PK resistance
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harbouring predominantly type 1 PrP
res while Group 2 consisted
in VV and MV patients harbouring predominantly type 2 or type
1+2 PrP
res. Groups 3 and 4 were respectively composed with VV1
and MM2 patients from our sCJD panel.
Striking differences were observed in the PrP
Sc properties
between the different iCJD cases and all four groups relying on
PrP
Sc signatures observed in sCJD cases were identified (Table 1,
and Figures 3B and 4).
As it might have been expected from sCJD cases observations,
Group 1 PrP
Sc properties was identified in MM1 UK dura mater
graft patients (n=2) (Figure 4A) while Group 2 PrP
Sc features were
observed in UK VV2 (n=2) (Figure 4D) and MV2 (n=1)
(Figure 4B) GH patients. Surprisingly, a typical Group 2 PrP
Sc
signature was also observed in one out of the three MV1 French
GH patients (type 1 in all brain areas). Meanwhile, all investigated
MM1 and two out of the three MV1 French GH cases (Figure 4A)
harboured identical PrP
Sc properties than Group 3 sCJD
(Figure 4E). Finally, a Group 4 sCJD PrP
Sc signature (Figure 4F)
was observed, using both PrP
Sc resistance ELISA (Figure 4E) and
strain typing ELISA (Figure 3B), in a French dura mater VV1 case
(n=1), which harboured a type 1 PrP
res WB profile in every
investigated area.
Taken together, these observations support the concept that, in
iCJD patients, variability in the PrP
Sc biochemical properties is not
related to the route of infection or the PRNP codon 129 genotype.
It also indirectly suggests that the range of different PrP
Sc
properties observed in iCJD might be related to those in the
source of infection (likely to have been a sCJD case).
Discussion
Coexistence of Different PrP
res Types in the Same Subject
In this study, detection, by WB, of the coexistence of two PrP
res
types in about 30% (13/41) of cases is consistent with already
published data [12,14]. This observation could suggest the
existence in brain from a single patient of different abnormal
PrP species. Although two main PK cleavage sites are associated
with PrP
res type 1 and type 2 (respectively amino acid 82 and 97),
N-terminal sequencing revealed in all investigated cases the
presence of a whole spectrum of overlapping cleavage sites.
Moreover in a part of investigated cases this technique
demonstrated the presence (i) of variable but consistent level of
type 1 PrP
res in patients classified type 2 using WB and (ii) in some
patient classified type 1, of low amount of type 2 PrP
res [10]. These
observations could suggest that, rather than a pure type 1 or type 2
PrP
res, PK digestion of a PrP
Sc specific conformer generate
variable mixture of PrP
res fragments (with presence of dominant or
sub dominant type 1 or type 2 PrP
res), which WB usually failed to
reveal accurately because its intrinsic technical limits [14].
Antibodies either harbouring higher affinity to PrP (like Sha31)
[18] or probing specifically type 1 PrP
res (like 12B2) [20], now
allow a better perception of such mixture. However, investigations
carried out using artificial mixture of type 1 and type 2 brain
homogenate, even using high affinity anti-PrP antibodies, clearly
indicate the current limits of WB discriminative power [14].
Together, these data suggest that WB analysis of PrP
res on its own
could be misleading for adequate discrimination between PrP
Sc
variants in CJD.
Both PrP
Sc PK resistance ELISA and strain typing ELISA are
based on the characterization the N terminal part of the PrP
Sc PK
digestion either by increasing PK amount or modifying detergent
conditions. While WB profile could be compared to a snapshot
picture of PrP
res fragments generated by PK digestion process,
these assays reflect the dynamics of the PK cleavage rather than its
final result (different forms of PrP
res). Consequently they could
provide different but also more accurate perception of the PrP
Sc
conformers.
Our findings from the PrP
Sc capture immunoassays clearly
indicate that in a single patient, irrespective of brain area, sCJD
associated PrP
Sc displays uniform biochemical properties, regard-
less of the regional variation of type 1 and type 2 isoforms
determined by WB. Such findings support the idea of the presence
of a specific TSE agent in each brain and the accumulation of a
single associated PrP
Sc conformer.
sCJD Classification
Because the limited size of our cohort of cases, an in depth
comparison between the PrP
Sc signature (as established in this
study) and the Parchi classification system is not possible.
However, despite this limitation, two major groups were
identified in our panel according to the PrP
Sc properties. The
first major group was constituted with patients harbouring a highly
PK resistant PrP
Sc (MM1 and MV1 patients). The second group
included patients harboring a PK labile PrP
Sc (VV2 and MV2
patients). Using both lesion profile and clinical parameters [2], two
major forms of sCJD are commonly recognized. The first sCJD
form, named ‘‘classical’’, is characterized by a ‘‘rapid evolution’’
(usually around 4 months), and affects most of the MM1 and MV1
patients. The second sCJD form, named ‘‘atypical’’, affects VV2
and MV2 with a longer symptomatic evolution (usually longer
than 6 months) and a late dementia. Despite inter-individual
variations, sCJD Groups 1 and 2, as we defined them on
biochemical criteria were consistent with this classification.
Both VV1 and MM2 sCJD cases are extremely rare; they
respectively represent 1% and 4% of the identified sCJD cases.
According to the literature, these patients have clinical features
and lesion profiles that are very different from other sCJD patients
[2]. However, in our study as in previously published studies, WB
did not identify any distinct biochemical difference from other type
1 and type 2 cases. In contrast, both the strain typing ELISA and
PrP
Sc resistance assays clearly differentiated these cases from
Group 1 and Group 2 cases. This finding, which is consistent with
clinico/pathological observations carried out in patients, could
indicate that there are indeed differences in PrP
Sc that distinguish
these VV1 and MM2 cases from other sCJD groups.
assay in three areas from a (C) VV (triangles) or MM (circles) patient and in (D) a MV (triangles) patient harbouring distinct PrP
Sc WB type in their
different brain areas. Artificial mixtures of MM2/VV1 or MM1/VV2 samples were prepared. All homogenates were first equilibrated by dilution into
negative brain homogenate to obtain an equal PrP
Sc signal in ELISA. (E, F) Mixtures were then tested by Western Blot (200 mg PK digestion—Sha31
anti PrP antibody). (E) Lane 1: MM1 100%; Lane 2: MM1 75%/VV2 25%; Lane 3: MM1 50%/VV2 50%; Lane 4: MM1 25%/VV2 75%; Lane 5: VV2 100%. (F)
Lane 1: VV1 100%; Lane 2: VV1 75%/MM2 25%; Lane 3: VV1 50%/MM2 50%; Lane 4: VV1 25%/MM2 75%; Lane 5: MM2 100%. (G, H) Same mixtures
were tested in the PK resistance ELISA assay. (G) VV2 100% (filled circles), VV2 75%/MM1 25% (filled triangles), VV2 50%/MM1 50% (filled inverted
triangles), VV2 25%/MM1 75% (open triangles), MM1 100% (open circles). (H) MM2 100% (filled circles), MM2 75%/VV1 25% (filled triangles), MM2
50%/VV1 50% (filled inverted triangles), MM2 25%/VV1 75% (open triangles), VV1 100% (open circles).
doi:10.1371/journal.ppat.1000029.g003
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PLoS Pathogens | www.plospathogens.org 7 2008 | Volume 4 | Issue 3 | e1000029Figure 4. PK Resistance ELISA in Frontal Cortex from sCJD and French or UK iCJD (Growth Hormone and Dura Mater Cases). sCJD
(solid line) and i-CJD (dashed line) frontal cortex samples were investigated by PK resistance assay. (A) MM1 sCJD cases (open circles, hexagons and
squares), MM1 iCJD UK dura mater cases (open diamonds), MM1 French GH cases (open triangles). (B) MV2 sCJD cases (filled circles, hexagons and
squares) and MV2 UK GH case (filled triangles). (C) MV1 sCJD (open circles, diamonds and squares) and MV1 French GH (open triangles) cases. (D) VV2
sCJD (filled circles and hexagons) and VV2 UK GH (filled triangles) cases. (E) VV1 sCJD case (open circles) and VV1 dura mater French case (open
triangles). (F) MM2 sCJD cases (filled circles and triangles).
doi:10.1371/journal.ppat.1000029.g004
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Sc Phenotype
Although prion strains can only be identified definitively by
bioassay, molecular in vitro tools to characterize PrP
Sc are more
and more widely used for the rapid identification of particular
agents, such as BSE in cattle, sheep, rodent and humans (vCJD)
[20,21]. This has come to be termed ‘‘molecular strain typing’’
and although widely employed, the exact relationship between
PrP
Sc biochemistry and the biological properties of the agents
responsible remain to be determined. In sCJD, the presence of
four distinct PrP
Sc biochemical forms apparently correlated to
clinico-pathological phenotypes as defined by Parchi et al. [2]
could be an indication of the involvement of different TSE agents.
iCJD cases are a consequence of accidental human to human
TSE transmission, most likely representing transmission of sCJD.
The identification in iCJD cases of the four PrP
Sc signatures
identified in sCJD is consistent with the existence of distinct prions
associated with these biochemical forms.
Three examples of human-to-human transmission of variant
CJD through blood transfusion have now been identified. While
all blood donors were MM at codon 129 PRNP, the recipients had
either a MM (n=2) or a MV genotype (n=1). Despite this
genotype difference there appears to have been conservation of the
disease phenotype and PrP
res type in all ‘‘secondary’’ vCJD cases
[22–25]. These observations could suggest that in case of inter-
human transmission, difference in donor/recipient genotype could
result in un-altered abnormal PrP signature.
Our identification of MM GH iCJD cases harbouring similar
PrP
Sc signature as a VV1 sCJD case or of a VV dura mater iCJD
case similar to MM2 sCJD might indicate preservation of a specific
PrP
Sc biochemical signature after human to human transmission
between individuals of different codon 129 genotypes.
Treatment with extracts of GH contaminated by CJD has lead
to a high number of iCJD cases in France and the UK. The codon
129 genotypes of the affected individuals in the two countries
differ, with the French cohort predominantly MM and MV and
the British cohort MV and VV [26]. In the absence of any clear
explanation for this finding, it was suggested that it might be due to
contamination of different batches of GH with different prion
strains from individuals of differing PRNP codon 129 genotypes.
Our identification of different biochemical forms of PrP
Sc in GH
French patients and in UK patients is consistent with this
hypothesis. The variability observed within the French GH cases
could signify involvement of different prion strains, consistent with
multiple contaminated GH batches in the French epidemic.
Conclusion
The identification in this study of different PrP
Sc species in CJD
patients with the same PRNP polymorphism at codon 129 and WB
PrP
res profile offers a new perspective on our understanding of the
relationship between PrP biochemistry, prion disease phenotype
and agent strain. We highlight two novel approaches to analysing
PrP
Sc in sCJD and iCJD and offer evidence that these analyses
provide potentially-strain associated information, which appears to
be lacking from the conventional WB assay.
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